Product Description
Ocriplasmin (JETREA(®)) is a recombinant human serine protease plasmin with proteolytic activity against the protein components (e.g. laminin, fibronectin and collagen) of the vitreous and vitreoretinal interface, thereby facilitating vitreous liquefaction and separation of vitreous from the retina. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24062204/)
Mechanisms of Action: Fibronectin Antagonist,Laminin Antagonist,ELA Activator,MMP Activator
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Cyprus | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Peru | Poland | Portugal | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: ThromboGenics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20241893 | P1 |
Recruiting |
Unknown |
None |